Table 1.
Levels of ΔDiHS-0S and ΔDiHS-NS in patients with MPS control subjects over 3 years of age.
| ΔDiHS-0S (ng/ml) | ΔDiHS-NS (ng/ml) | |
|---|---|---|
| Control | 27.5 ± 8.7 | 22.7 ± 4.8 |
| Untreated MPS II (severe) | 144.5 ± 77.9a | 89.4 ± 100.1a |
| ERT-treated MPS II (severe) | 116.1 ± 101.0a | 61.0 ± 41.4 |
| HSCT-treated MPS II (severe) | 40.3 ± 11.1b,c | 34.1 ± 5.9 |
| Untreated MPS II (attenuated) | 49.2 ± 21.9b | 32.2 ± 11.5 |
| ERT-treated MPS II (attenuated) | 30.5 | 22 |
Number of each group is as follows; control (n = 59), untreated MPS II (severe; n = 24), ERT-treated MPS II (severe; n = 15), HSCT-treated MPS II (severe; n = 6), untreated MPS II (attenuated; n = 9), and ERT-treated MPS II (attenuated; n = 1).
a
significantly different from the control at p < 0.05,
b
significantly different from the untreated MPS II severe at p < 0.05,
c
significantly different from the ERT-treated MPS II severe at p < 0.05